docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2023-22-3-40-44docru-310Research ArticleПУЛЬМОНОЛОГИЯPULMONOLOGYАнализ вариантов противовоспалительной терапии облитерирующего бронхиолита у детейAnalysis of Anti-Inflammatory Therapy Options for Bronchiolitis Obliterans in Childrenhttps://orcid.org/0000-0002-9670-9211ПотаповаН. Л.PotapovaN. L.

Потапова Наталья Леонидовна — д. м. н., доцент, заведующая кафедрой поликлинической педиатрии

672000, г. Чита, ул. Горького, д. 39а

39а Gor’kogo Str., Chita, 672000

nataliapotap@yandex.ruhttps://orcid.org/0000-0002-1796-2711МарковскаяА. И.MarkovskayaA. I.

Марковская Анжелика Игоревна — к. м. н., ассистент кафедры педиатрии

672000, г. Чита, ул. Горького, д. 39а

39а Gor’kogo Str., Chita, 672000

anzhelika_petrova_1992@mail.ruФГБОУ ВО «Читинская государственная медицинская академия» Министерства здравоохранения Российской ФедерацииРоссияChita State Medical AcademyRussian Federation202320022025223ПЕДИАТРИЯ4044Copyright © Потапова Н.Л., Марковская А.И., 20252025Потапова Н.Л., Марковская А.И.Potapova N.L., Markovskaya A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/310Цель обзора

Цель обзора: представить актуальную информацию о новых подходах к терапии облитерирующего бронхиолита у детей, основанную на данных зарубежных исследователей.

Основные положения

Основные положения. Облитерирующий бронхиолит является необратимым хроническим обструктивным заболеванием легких, сопровождающимся дыхательной недостаточностью, существенным снижением качества жизни, формированием стойких признаков инвалидности. Несмотря на значительный интерес к данной проблеме, остаются актуальными вопросы тактики ведения пациентов и подбора алгоритмов эффективной терапии. Риск развития побочных явлений при применении системных кортикостероидов обосновывает поиск альтернативных схем терапии. В обзоре представлена информация о комбинированном использовании ингаляционных кортикостероидов, азитромицина, монтелукаста и N-ацетилцистеина.

Заключение

Заключение. Дальнейшая разработка альтернативных схем терапии хронического облитерирующего бронхиолита может помочь в достижении эффективного контроля над данным заболеванием.

Aim

Aim: To present the relevant information on the new approaches to the management of obliterating bronchiolitis in children, based on the data generated by foreign researchers.

Key Points

Key Points. Obliterating bronchiolitis is a non-reversible chronic obstructive lung disease associated with respiratory insufficiency, significant deterioration in the quality of life, and steady signs of disability. Despite the fact that this topic is of high interest, the management of patients and efficient therapy algorithms are a burning issue. A risk of side effects from systemic corticosteroids necessitates the search for alternative therapies. This overview presents information on a combined use of inhaled corticosteroids, azithromycin, monteleukast, and N-acetylcysteine.

Conclusion

Conclusion. Further development of alternative therapies for chronic obliterating bronchiolitis can help in achieving efficient control of this disease.

облитерирующий бронхиолиттерапиядетиobliterating bronchiolitistherapychildrenАвторы заявляют об отсутствии внешнего финансирования при проведении исследования.This study was not supported by any external sources of funding.ReferencesKavaliunaite E., Aurora P. Diagnosing and managing bronchiolitis obliterans in children. Expert Rev. Respir. Med. 2019;13(5):481– 488. DOI: 10.1080/17476348.2019Kavaliunaite E., Aurora P. Diagnosing and managing bronchiolitis obliterans in children. Expert Rev. Respir. Med. 2019;13(5):481– 488. DOI: 10.1080/17476348.2019Fischer G.B., Sarria E.E., Mattiello R. et al. Post infectious bronchiolitis obliterans in children. Paediatr. Respir. Rev. 2010;11(4):233–239. DOI: 10.1016/j.prrv.2010.07.005Fischer G.B., Sarria E.E., Mattiello R. et al. Post infectious bronchiolitis obliterans in children. Paediatr. Respir. Rev. 2010;11(4):233–239. DOI: 10.1016/j.prrv.2010.07.005Бойцова Е.В., Овсянников Д.Ю. Постинфекционный облитерирующий бронхиолит у детей. Детские инфекции. 2014;(2):24–28.Boitsova E.V., Ovsyannikov D.Yu. Postinfectious obliterans bronchiolitis in children. Childhood infections. 2014;(2):24–28. (in Russian)Li Y.N., Liu L., Qiao H.M. et al. Post-infectious bronchiolitis obliterans in children: a review of 42 cases. BMC Pediatr. 2014;14:238. DOI: 10.1186/1471-2431-14-238Li Y.N., Liu L., Qiao H.M. et al. Post-infectious bronchiolitis obliterans in children: a review of 42 cases. BMC Pediatr. 2014;14:238. DOI: 10.1186/1471-2431-14-238Yu X., Ma Y., Gao Y., You H. Epidemiology of adenovirus pneumonia and risk factors for bronchiolitis obliterans in children during an outbreak in Jilin, China. Front. Pediatr. 2021;9:722885. DOI: 10.3389/fped.2021.722885Yu X., Ma Y., Gao Y., You H. Epidemiology of adenovirus pneumonia and risk factors for bronchiolitis obliterans in children during an outbreak in Jilin, China. Front. Pediatr. 2021;9:722885. DOI: 10.3389/fped.2021.722885Бочкарева Л.С., Мироманова Н.А. Клинические особенности острого вирусного бронхиолита у детей с предикторами тяжести. Забайкальский медицинский вестник. 2022;(1):71–80.Бочкарева Л.С., Мироманова Н.А. Клинические особенности острого вирусного бронхиолита у детей с предикторами тяжести. Забайкальский медицинский вестник. 2022;(1):71–80.Duecker R.P., De Mir Messa I., Jerkic S.P. et al. Epigenetic regulation of inflammation by microRNAs in post-infectious bronchiolitis obliterans. Clin. Transl. Immunol. 2022;11(2):e1376. DOI: 10.1002/cti2.1376Duecker R.P., De Mir Messa I., Jerkic S.P. et al. Epigenetic regulation of inflammation by microRNAs in post-infectious bronchiolitis obliterans. Clin. Transl. Immunol. 2022;11(2):e1376. DOI: 10.1002/cti2.1376Kang M.J., Ahn H.S., Lee S.Y. et al. TGFβ1 and POSTN as biomarkers of postinfectious bronchiolitis obliterans and asthma in children. Pediatr. Pulmonol. 2022;57(12):3161–3164. DOI: 10.1002/ppul.26139Kang M.J., Ahn H.S., Lee S.Y. et al. TGFβ1 and POSTN as biomarkers of postinfectious bronchiolitis obliterans and asthma in children. Pediatr. Pulmonol. 2022;57(12):3161–3164. DOI: 10.1002/ppul.26139Jerkic S.P., Brinkmann F., Calder A. et al. Postinfectious bronchiolitis obliterans in children: diagnostic workup and therapeutic options: a workshop report. Can. Respir. J. 2020;2020:5852827. DOI: 10.1155/2020/5852827Jerkic S.P., Brinkmann F., Calder A. et al. Postinfectious bronchiolitis obliterans in children: diagnostic workup and therapeutic options: a workshop report. Can. Respir. J. 2020;2020:5852827. DOI: 10.1155/2020/5852827Colom A.J., Teper A.M. Post-infectious bronchiolitis obliterans. Pediatr. Pulmonol. 2019;54(2):212–219. DOI: 10.1002/ppul.24221Colom A.J., Teper A.M. Post-infectious bronchiolitis obliterans. Pediatr. Pulmonol. 2019;54(2):212–219. DOI: 10.1002/ppul.24221Спичак Т.В. Облитерирующий бронхиолит в детском возрасте — это болезнь или синдром? Педиатрия. 2016;95(4):124– 130.Спичак Т.В. Облитерирующий бронхиолит в детском возрасте — это болезнь или синдром? Педиатрия. 2016;95(4):124– 130.Lee G.M., Carroll M.B., Galvin J.R., Walker C.M. Mosaic attenuation pattern: a guide to analysis with HRCT. Radiol. Clin. North. Am. 2022;60(6):963–978. DOI: 10.1016/j.rcl.2022.06.009Lee G.M., Carroll M.B., Galvin J.R., Walker C.M. Mosaic attenuation pattern: a guide to analysis with HRCT. Radiol. Clin. North. Am. 2022;60(6):963–978. DOI: 10.1016/j.rcl.2022.06.009Mauad T., Dolhnikoff M., São Paulo Bronchiolitis Obliterans Study Group. Histology of childhood bronchiolitis obliterans. Pediatr. Pulmonol. 2002;33(6):466–474. DOI: 10.1002/ppul.10097Mauad T., Dolhnikoff M., São Paulo Bronchiolitis Obliterans Study Group. Histology of childhood bronchiolitis obliterans. Pediatr. Pulmonol. 2002;33(6):466–474. DOI: 10.1002/ppul.10097Chen I.C., Hsu J.S., Chen Y.W. et al. Post-infectious bronchiolitis obliterans: HRCT, DECT, pulmonary scintigraphy images, and clinical follow-up in eight children. Front. Pediatr. 2020;8:622065. DOI: 10.3389/fped.2020.622065Chen I.C., Hsu J.S., Chen Y.W. et al. Post-infectious bronchiolitis obliterans: HRCT, DECT, pulmonary scintigraphy images, and clinical follow-up in eight children. Front. Pediatr. 2020;8:622065. DOI: 10.3389/fped.2020.622065Maia S.A., Eli D., Cunha R. et al. Clinical, functional, and cytological evaluation of sputum in postinfectious bronchiolitis obliterans: a possible overlap with asthma? J. Bras. Pneumol. 2019;45(5):e20190060. DOI: 10.1590/1806-3713/e20190060Maia S.A., Eli D., Cunha R. et al. Clinical, functional, and cytological evaluation of sputum in postinfectious bronchiolitis obliterans: a possible overlap with asthma? J. Bras. Pneumol. 2019;45(5):e20190060. DOI: 10.1590/1806-3713/e20190060Mattiello R., Vidal P.C., Sarria E.E. et al. Evaluating bronchodilator response in pediatric patients with post-infectious bronchiolitis obliterans: use of different criteria for identifying airway reversibility. J. Bras. Pneumol. 2016;42(3):174–178. DOI: 10.1590/S1806-37562015000000065Mattiello R., Vidal P.C., Sarria E.E. et al. Evaluating bronchodilator response in pediatric patients with post-infectious bronchiolitis obliterans: use of different criteria for identifying airway reversibility. J. Bras. Pneumol. 2016;42(3):174–178. DOI: 10.1590/S1806-37562015000000065Yu X., Wei J., Li Y. et al. Longitudinal assessment of pulmonary function and bronchodilator response in pediatric patients with postinfectious bronchiolitis obliterans. Front. Pediatr. 2021;9:674310. DOI: 10.3389/fped.2021.674310Yu X., Wei J., Li Y. et al. Longitudinal assessment of pulmonary function and bronchodilator response in pediatric patients with postinfectious bronchiolitis obliterans. Front. Pediatr. 2021;9:674310. DOI: 10.3389/fped.2021.674310Mosquera R.A., Hashmi S.S., Pacheco S.E. et al. Dysanaptic growth of lung and airway in children with post-infectious bronchiolitis obliterans. Clin. Respir. J. 2014;8(1):63–71. DOI: 10.1111/crj.12037Mosquera R.A., Hashmi S.S., Pacheco S.E. et al. Dysanaptic growth of lung and airway in children with post-infectious bronchiolitis obliterans. Clin. Respir. J. 2014;8(1):63–71. DOI: 10.1111/crj.12037Jung J.H., Kim G.E., Min I.K. et al. Prediction of postinfectious bronchiolitis obliterans prognosis in children. Pediatr. Pulmonol. 2021;56(5):1069–1076. DOI: 10.1002/ppul.25220Jung J.H., Kim G.E., Min I.K. et al. Prediction of postinfectious bronchiolitis obliterans prognosis in children. Pediatr. Pulmonol. 2021;56(5):1069–1076. DOI: 10.1002/ppul.25220Cheng Q., Zhang H., Shang Y. et al. Clinical features and risk factors analysis of bronchitis obliterans due to refractory Mycoplasma pneumoniae pneumonia in children: a nomogram prediction model. BMC Infect. Dis. 2021;21(1):1085. DOI: 10.1186/s12879-021-06783-4Cheng Q., Zhang H., Shang Y. et al. Clinical features and risk factors analysis of bronchitis obliterans due to refractory Mycoplasma pneumoniae pneumonia in children: a nomogram prediction model. BMC Infect. Dis. 2021;21(1):1085. DOI: 10.1186/s12879-021-06783-4Chen D.H., Lin Y.N., Lan S.L. et al. Clinical characteristics of bronchiolitis obliterans in pediatric patients. Zhonghua Er Ke Za Zhi. 2012;50(2):98–102.Chen D.H., Lin Y.N., Lan S.L. et al. Clinical characteristics of bronchiolitis obliterans in pediatric patients. Zhonghua Er Ke Za Zhi. 2012;50(2):98–102.Wang X., Liu C., Wang M. et al. Clinical features of post-infectious bronchiolitis obliterans in children undergoing long-term azithromycin treatment. Exp. Ther. Med. 2015;9(6):2379–2383. DOI: 10.3892/etm.2015.2418Wang X., Liu C., Wang M. et al. Clinical features of post-infectious bronchiolitis obliterans in children undergoing long-term azithromycin treatment. Exp. Ther. Med. 2015;9(6):2379–2383. DOI: 10.3892/etm.2015.2418Zheng H., Yu X., Chen Y. et al. Effects of inhaled corticosteroids on lung function in children with post-infectious bronchiolitis obliterans in remission. Front. Pediatr. 2022;10:827508. DOI: 10.3389/fped.2022.827508Zheng H., Yu X., Chen Y. et al. Effects of inhaled corticosteroids on lung function in children with post-infectious bronchiolitis obliterans in remission. Front. Pediatr. 2022;10:827508. DOI: 10.3389/fped.2022.827508Jimenez A., De Jesús-Rojas W. Mycoplasma pneumoniae and Bronchiolitis obliterans: how a common organism leads to a rare pulmonary disease in pediatrics. Cureus. 2021;13(8):e17193. DOI: 10.7759/cureus.17193Jimenez A., De Jesús-Rojas W. Mycoplasma pneumoniae and Bronchiolitis obliterans: how a common organism leads to a rare pulmonary disease in pediatrics. Cureus. 2021;13(8):e17193. DOI: 10.7759/cureus.17193Lee E., Park S., Yang H.J. Pulmonary function in post-infectious bronchiolitis obliterans in children: a systematic review and meta-analysis. pathogens. 2022;11(12):1538. DOI: 10.3390/pathogens11121538Lee E., Park S., Yang H.J. Pulmonary function in post-infectious bronchiolitis obliterans in children: a systematic review and meta-analysis. pathogens. 2022;11(12):1538. DOI: 10.3390/pathogens11121538Weng T., Lin X., Wang L. et al. Follow-up on the therapeutic effects of a budesonide, azithromycin, montelukast, and acetylcysteine (BAMA) regimen in children with post-infectious bronchiolitis obliterans. J. Thorac. Dis. 2021;13(8):4775–4784. DOI: 10.21037/jtd-20-3195Weng T., Lin X., Wang L. et al. Follow-up on the therapeutic effects of a budesonide, azithromycin, montelukast, and acetylcysteine (BAMA) regimen in children with post-infectious bronchiolitis obliterans. J. Thorac. Dis. 2021;13(8):4775–4784. DOI: 10.21037/jtd-20-3195Sun J., Li Y. Long-term, low-dose macrolide antibiotic treatment in pediatric chronic airway diseases. Pediatr. Res. 2022;91(5):1036– 1042. DOI: 10.1038/s41390-021-01613-4Sun J., Li Y. Long-term, low-dose macrolide antibiotic treatment in pediatric chronic airway diseases. Pediatr. Res. 2022;91(5):1036– 1042. DOI: 10.1038/s41390-021-01613-4Williams K.M., Cheng G.S., Pusic I. et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2016;22(4):710–716. DOI: 10.1016/j.bbmt.2015.10.009Williams K.M., Cheng G.S., Pusic I. et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2016;22(4):710–716. DOI: 10.1016/j.bbmt.2015.10.009Chen X., Shu J.H., Huang Y. et al. Therapeutic effect of budesonide, montelukast and azithromycin on post-infectious bronchiolitis obliterans in children. Exp. Ther. Med. 2020;20(3):2649–2656. DOI: 10.3892/etm.2020.8983Chen X., Shu J.H., Huang Y. et al. Therapeutic effect of budesonide, montelukast and azithromycin on post-infectious bronchiolitis obliterans in children. Exp. Ther. Med. 2020;20(3):2649–2656. DOI: 10.3892/etm.2020.8983Dalby C., Polanowski T., Larsson T. et al. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir. Res. 2009;10(1):104. DOI: 10.1186/1465-9921-10-104Dalby C., Polanowski T., Larsson T. et al. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir. Res. 2009;10(1):104. DOI: 10.1186/1465-9921-10-104Jerkic S.P., Koc-Günel S., Herrmann E. et al. Long-term course of bronchial inflammation and pulmonary function testing in children with postinfectious bronchiolitis obliterans. Pediatr. Pulmonol. 2021;56(9):2966–2972. DOI: 10.1002/ppul.25547Jerkic S.P., Koc-Günel S., Herrmann E. et al. Long-term course of bronchial inflammation and pulmonary function testing in children with postinfectious bronchiolitis obliterans. Pediatr. Pulmonol. 2021;56(9):2966–2972. DOI: 10.1002/ppul.25547Okunishi K., Peters-Golden M. Leukotrienes and airway inflammation. Biochim. Biophys. Acta. 2011;1810(11):1096–1102. DOI: 10.1016/j.bbagen.2011.02.005Okunishi K., Peters-Golden M. Leukotrienes and airway inflammation. Biochim. Biophys. Acta. 2011;1810(11):1096–1102. DOI: 10.1016/j.bbagen.2011.02.005Blasi F., Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir. Med. 2016;117:190–197. DOI: 10.1016/j.rmed.2016.06.015Blasi F., Page C., Rossolini G.M. et al. The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respir. Med. 2016;117:190–197. DOI: 10.1016/j.rmed.2016.06.015

The authors declare that there are no conflicts of interest present.